Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond.

ABSTRACT: For patients with advanced cancers there has been a concerted effort to transition from a generic treatment paradigm to one based on tumor-specific biologic, and patient-specific clinical characteristics. This approach, known as precision therapy has been made possible owing to widespread availability and a reduction in the cost of cutting-edge technologies that are used to study the genomic, proteomic, and metabolic attributes of individual tumors. This review traces the evolution of precision therapy for lung cancer from the identification of molecular subsets of the disease to the development and approval of tyrosine kinase, as well as immune checkpoint inhibitors for lung cancer therapy. Challenges of the precision therapy era including the emergence of acquired resistance, identificat

SUBMITTER: Rajan A 

PROVIDER: S-EPMC6360071 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature